Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bluebird’s Zynteglo Approval Kicks Off Commercial Operations

Beta-Thalassemia Gene Therapy’s List Price Is $2.8m

Aug 18 2022

• By Mandy Jackson

business people stacking cogwheels in team — Bluebird already has assembled the provider, payer and patient support pieces of its commercial operations • Source: Shutterstock

Related Content

Bluebird Could Find US Tailwind For Zynteglo After ICER Report

Jun 02 2022

Bluebird Bio Restructures Amid Financial Woes, But Will It Fly?

Apr 05 2022

Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort

Aug 09 2021

Zynteglo Could Be Gene Therapy Test Case For Viability Of Outcomes-Based Contracts – UHC Exec

Jun 21 2022

Gene Therapy: Bluebird’s Beti-Cel Sails Through US Panel Review On Strength of ‘Impressive’ Efficacy

Jun 10 2022

Related Companies

Genetix Biotherapeutics

Additional Topics

Launches Pricing Strategies Reimbursement Approvals Gene Therapy Rare Diseases Commercial BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window